Arpraziquantel
- P02BA03 (WHO)
- 57452-98-9
- 445900
- DB11749
- 393394
- WF15T5925V
- D12741
- ChEMBL1235551
- PZQ (PDBe, RCSB PDB)
- DTXSID80904739
- Interactive image
- [H][C@@]12CN(CC(=O)N1CCC1=CC=CC=C21)C(=O)C1CCCCC1
- InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2/t17-/m0/s1
- Key:FSVJFNAIGNNGKK-KRWDZBQOSA-N
Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, and is a medication which is currently under investigation for the treatment of schistosomiasis in young children since it has less side effects than the usual racemic mixture formulation of praziquantel.[1]
Society and culture
Legal status
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children.[1] The applicant for this medicinal product is Merck Europe B.V.[1] It is intended exclusively for markets outside the European Union.[1]
Names
Arpraziquantel is the International nonproprietary name.[2]
References
- ^ a b c d "Arpraziquantel". European Medicines Agency. 14 December 2023. Archived from the original on 20 December 2023. Retrieved 20 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
Further reading
- Zdesenko G, Mutapi F (September 2020). "Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models". PLOS Neglected Tropical Diseases. 14 (9): e0008649. doi:10.1371/journal.pntd.0008649. PMC 7518612. PMID 32976496.
- v
- t
- e
Antitrematodals (schistosomicides) |
| ||||||
---|---|---|---|---|---|---|---|
Anticestodals (taeniacides) |
|
(including
macrofilaricides)
Binds tubulin | |
---|---|
Glutamate-gated chloride channel, GABA receptor | |
NMDA |
|
Other/unknown |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e